viewImmunoPrecise Antibodies Ltd

ImmunoPrecise Antibodies unveils antibody-engineering platform Abthena

Abthena produces bispecific antibodies, which don't occur naturally but can better target infectious diseases

Bispecific antibodies
ImunoPrice has designed a platform to discover the wild-type and fully human components of bispecific antibodies

ImmunoPrecise Antibodies Ltd (CVE:IPA) (OTCMKTS:IPATF) has launched its Abthena bispecific antibodies platform and its complementary Artemis Intelligence Metadata capabilities.

Bispecific antibodies are an engineered class of antibodies and antibody-like proteins that don’t occur naturally. What makes the Abthena bispecifics unique is the ability to bind two different molecules with a single antibody, the company explained in a statement Monday, 

This gives them an advantage over naturally-occurring monospecific antibodies in targeting infectious diseases, maximizing payload delivery and improving functional activity toward particularly challenging targets. 

READ:ImmunoPrecise reports record fiscal full-year revenue following European expansion

Conversely, Abthena bispecifics can also dual target, which allows for the detection or binding of a target cell type with higher specificity. 

ImunoPrice has designed a platform to discover the wild-type and fully human components of bispecific antibodies, which means it can generate pairs of bound proteins with antibody backbones and the attributes necessary to bind to molecules. 

The Abthena platform meshes with Artemis Intelligence Metadata, which offers rapid turnaround on additional algorithmic outputs regarding therapeutic optimization, stability, affinity and manufacturability of the antibodies.

More broadly, ImmunoPrecise is a full-service antibody discovery company. Its goal is to deliver its clients with therapeutically significant custom antibodies that have the greatest probability of ultimately succeeding in clinical trials.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: ImmunoPrecise Antibodies Ltd

Price: 10.1 CAD

Market: TSX-V
Market Cap: $169.29 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmunoPrecise Antibodies Ltd named herein, including the promotion by the Company of ImmunoPrecise Antibodies Ltd in any Content on the Site,...


ImmunoPrecise Antibodies reveals 39% growth in 1Q revenue, initiates...

ImmunoPrecise Antibodies Ltd. (TSX-V:IPA) (OTCQB:IPATF) CEO Dr Jennifer Bath tells Proactive the technology platform company reported revenue increases by 39%, to $3.8 million in its first quarter financials, while the company initiates its pre-clinical coronavirus vaccine study. Bath says new...

on 09/30/2020

2 min read